What diseases does Upadacitinib treat?

Upadacitinib (Upadacitinib) is a class of drugs called Janus kinase (JAK) inhibitors, which work by reducing the activity of the immune system. Upadatinib is an extended-release (long-acting) tablet that is usually taken once daily with or without food and is used alone or with other medicines to treat the following conditions, according to its prescribing guidelines:

1. Treat rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain, swelling and loss of function) in people who cannot take or do not respond well to one or more tumor necrosis factor (TNF) inhibitor drugs;

2. Treatment of psoriatic arthritis (a disease that causes joint pain, skin swelling, and scaling) in adults who are unable to take, or have not responded to or tolerated one or moreTNF inhibitor drugs;

3. Treat symptoms of eczema (atopic dermatitis; a skin disease that causes dry, itchy skin, sometimes with a red, scaly rash) in adults andchildren 12 years and older who cannot use other medications to treat their condition or whose eczema does not respond to other medications;

4. Treat ulcerative colitis (a disease that causes swelling and ulcers in the lining of the colon [large intestine] and rectum) in adults who cannot take or respond to one or moreTNF inhibitor drugs;

5. Treat Crohn's disease (a disease in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss and fever) in adults who cannot take or do not respond to one or moreTNF inhibitor drugs;

6. Treat ankylosing spondylitis (a disease in which the body attacks joints in the spine and elsewhere, causing pain, swelling and joint damage) in adults who cannot take or do not respond to one or more TNF inhibitor drugs.

7. Treats active non-radiographic axial spondyloarthritis (a disease in which the body attacks the joints and other parts of the spine, causing signs of pain and swelling), but without visible changes on X-rays in adults who cannot take or do not respond to one or more TNF inhibitor drugs.

The original drug Upatinib has been launched in China, and has subsequently entered the scope of Class B medical insurance. Only eligible patients can be reimbursed. Specifications The price of each box of 15mg*28 tablets may be around RMB 3,000. The European version of the original drug sold overseas, with a specification of 15mg*30 tablets, costs more than 20,000 yuan (prices may fluctuate due to exchange rates), expensive. Cheaper upadatinib generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 15mg*30 tablets produced by Bangladesh pharmaceutical factory is around 900 yuan (the price may fluctuate due to the exchange rate).